SESSION I: CAR-T, update clinical trials and RWE

P. Corradini

HG-BCL
S.J. Schuster
Follicular lymphoma
C.A. Jacobson
SESSION II: Hodgkin’s lymphoma

S.M. Ansell, P.L. Zinzani

1st relapse
S.M. Ansell
Grey zone lymphoma
S.M. Ansell
Lectures on PROTAC therapies

B.D. Cheson

NX-2127
A.V. Danilov
BGB-16673
C. Cheah
SESSION III: Acute leukemias

A. Curti, A. Venditti

Menin-inhibitors
C. Papayannidis
SESSION IV: Classical Ph1-neg myeloproliferative neoplasms

F. Palandri, A.M. Vannucchi

SESSION V: Non-Hodgkin’s lymphoma (I)

C. Carlo-Stella, M. Ladetto

Tafasitamab
J.A. Duell
Epcoritamab
C. Thieblemont
Glofitamab
M. Dickinson
Mosunetuzumab
E.L. Budde
Odronextamab
W.S. Kim
TNB-486
R.W. Jacobs
Polatuzumab vedotin
B.D. Cheson
Tazemetostat
J.M. Michot
SESSION VI: Non-Hodgkin’s lymphoma (II)

M. Martelli, M. Spina

Zilovertamab
P.M. Barr
Linperlisib
S.P. Iyer
Pirtobrutinib
W. Jurczak
Golidocitinib
W.S. Kim
Valemetostat
S.M. Horwitz
Iberdomide
C. Thieblemont
Golcadomide
J.M. Michot
CDK9 inhibitors
J. Zain
SESSION VII: Non-Hodgkin’s lymphoma - The next steps of CAR-T

S.J. Schuster

New generations of CAR-T
S.J. Schuster
Allo CAR-T
S.S. Neelapu
CAR-NK cells
K. Rezvani
Gamma delta CART19
S.S. Neelapu
SESSION VIII: Chronic myeloid leukemia

M. Breccia, F. Castagnetti

Asciminib
D. Rea
Ponatinib
F. Castagnetti
Second generation TKIs
T.H. Bruemmendorf
New agents
M. Bonifacio
Lecture

N. Vianelli

SESSION IX: Chronic lymphocitic leukemia

W. Jurczak, A. Tedeschi

Ibrutinib
W. Jurczak
Venetoclax
O. Al-Sawaf
Acalabrutinib
J.C. Byrd
Zanubrutinib
J. Brown
Pirtobrutinib
W. Jurczak
Nemtabrutinib
J.C. Byrd
BGB-11417
C. Cheah
CAR-T
T. Siddiqi
SESSION X: Multiple myeloma

M. Cavo